03/31/2021 7:54 AM
Clarín.com
World
Updated 03/31/2021 8:45 AM
Pfizer announced on Wednesday that the coronavirus vaccine developed together with the German drug manufacturer BioNtech showed 100% effectiveness in boys between 12 and 15 years old, according to the result of a phase 3 clinical trial.
Phase 3 clinical trials in 2,260 adolescents in the United States "
showed 100% efficacy and a robust antibody response,
" the companies said in a statement.
The trial was conducted with adolescents in the United States between the ages of 12 and 15 years and in it,
18 cases of COVID 19
were detected
in the placebo group
, compared to none in the vaccinated group.
The entrance to the BioNTech laboratory in Germany, where the COVID vacuum is produced.
Photo: Bloomberg
This demonstrates "strong immunogenicity in a subgroup of adolescents
one month after the second dose
," according to the statement from both pharmaceutical companies, which indicates that the observed side effects were similar to those detected with the trial in the group between 16 and 25 years.
That response is "higher than previously recorded in vaccinated participants ages 16 to 25," according to the report.
Pfizer CEO Albert Bourla said the company plans to send the new vaccine data to the Food and Drug Administration, the US regulator, as well as other regulators
"as soon as possible
.
"
The idea, according to the executive, is that children in the age group can be
vaccinated before the start of the new school year,
next August.
For BioNTech CEO Uğur Şahin, the news is "
very encouraging
given the trends we have seen in recent weeks regarding the spread of the UK variant B.1.1.7."
In the same statement, it was reported that a clinical trial had begun last week to test the effectiveness of the vaccine in children
between 6 months and 11 years of age
.
A two-dose schedule, administered 21 days apart, is being tested in three groups: 6 months to 2 years, 2 to 5 years, and 5 to 11 years.
In this first phase, only those in the group between 5 and 11 years of age received their first dose.
The Pfizer and BioNTech vaccine, based on pioneering mRNA technology, was the first to be approved in the West.
Recently, they reported that they will seek to produce 2.5 billion doses in the remainder of 2021, thanks to a new production center that they opened in Germany.
In addition to this, there is another production plant in Belgium, and two more in the United States.
Source: agencies
JPE
Look also
The prescription for the coronavirus vaccine, available on the Internet?
Israel detected a new variant of the coronavirus
